Review Article

Metformin, a systematic review

ABSTRACT:

Metformin is the primary pharmacologic treatment of type II Diabetes also the most recommended drug around the world, either alone or in blend with insulin or other glucose-lowering treatments. Metformin is a biguanide. Metformin was likewise removed because of worries over lactic acidosis, but it consequently brought down glucose levels and was once again introduced in 1995.

Diabetes mellitus is a gathering of issues related to a metabolism where the glucose concentration of blood is higher than usual because of low discharge of insulin or inappropriate reactivity to insulin, bringing about hypertension. Therefore low glucose, results in cutting off intricacies. Metformin has been indicated to forestall diabetes for individuals who pose a greater danger and reduce the majority of diabetic confusion. Late responses to metformin indicated many more ramifications; for example, metformin has kidney protective characteristics.

With an expanding worldwide weight of CAD, early identification and convenient administration of hazard factors are pivotal to decreasing dismalness and mortality in such patients. DM is viewed as a free danger factor for the improvement of CAD. Metformin, a drug for diabetic medication, has a role in pre-clinical and clinical examinations to lower cardiovascular occasions in DM patients. Metformin protectively affects coronary veins past its hypoglycemic impacts. Given its worldwide accessibility, course of organization, and cost, metformin gives a different restorative choice for essential and optional anticipation of CAD in DM and non-diabetics.

Metformin has also shown remarkable improvements in patients with Polycystic ovarian syndrome.

Keywords – Metformin, lactic acidosis, type II diabetes mellitus, kidney protective, poly-cystic ovarian syndrome.

INTRODUCTION

A cluster of metabolic issues is related to diabetes wherein the glucose of blood showed increase than the ordinary bars because there is low insulin discharge either inappropriate reactivity to insulin, bringing about hypertension. The low glucose condition delivers the traditional manifestations of polyuria; polydipsia also increases appetite. It might disrupt functions related to the neural system, issues to renal, visual deficiency, appendage loss, problems related to intercourse, rise in coronary failure or stroke [1]. Metformin, a biguanide, regulates blood glucose levels, decreasing these problems. Metformin acts by assisting the reaction of the body to insulin. It also diminishes the glucose produced by the liver and the digestion tracts or absorption in the stomach.[2] Besides lowering glucose, metformin is advised and dietary changes and exercises to forestall diabetes in individuals with a high risk of diabetes. In females, it is likewise utilized to have polycystic ovarian syndrome. Metformin might make better standardization of menstrual cycles and improved fertility.[3] Metformin was blended and observed to diminish glucose levels in blood in the 1920s; be that as it may, it wasn't utilized for a time. The utilization of metformin was revived in the year 1957, at the point when the results of a clinical primer were dispersed, certifying its effect on diabetes. Metformin is presently broadly endorsed as a medication for high blood glucose, carrying many side effects, particularly ketoacidosis.[4] Recently, not just a few ramifications have been found for metformin, yet in addition, reports demonstrate that the drug has unfavorable impacts, which are immaterial when its advantages are seen altogether.[3] Theoretically, the utilization of the drug has been disallowed in a massive gathering of patients having diabetes Mellitus type due to lactic acidosis danger. Nonetheless, it has been displayed that a couple of patients having diabetes or who are viewed as in danger have gotten Metformin with no expanded lactic acidosis danger.[2,3,4,5] Besides, as of late, a few papers have been distributed demonstrating renoprotective properties for metformin.

MECHANISM OF ACTION

Studies have shown that metformin acts in the liver, restraining gluconeogenesis by hindering mitochondrial redox transport. Medication's belonging is probable pleiotropic. Metformin has likewise been demonstrated to be an insulin sensitizer to act in the gut lumen through different components. [6].

Applications of Metformin in various conditions

DIABETES MELLITUS

Metformin drug is fundamentally utilized for typeII diabetes mellitus treatment, especially in patients of obese nature. Metformin drug has been displayed to have decreased death and disarrays in diabetes by about a third contrasted with chlorpropamide, glibenclamide, and insulin.[5]

Metformin diminishes glucose level in serum by a few unique components, prominently through non-pancreatic systems without increasing insulin discharge. The impacts of insulin are built; subsequently, it is named "sensitizer of insulin." Metformin likewise stifles the liver for its glucose creation, chiefly because of the decreased pace of gluconeogenesis and a negligible impact on glycogenolysis. Besides, metformin enacts the compound adenosine monophosphate kinase bringing about restraint of main proteins engaged with gluconeogenesis and glycogen combination in the hepatocytes while animating insulin flagging and glucose transport in muscle cells. AMPK manages both cellulars with organ digestion and decline in any energy in hepatocytes, prompting AMPK enactment. This

review, to a degree, has progressed to explain the part of metformin movement on gluconeogenesis in hepatocytes. [7,8]

Besides, metformin fabricates the periphery glucose expulsion that commonly arises through extended non-oxidative glucose removal into voluntary muscles. Generally, it doesn't lower glucose levels, and this reason is taken as a remarkable enemy of drugs of diabetes.[9]

Diabetic treatment with metformin is related to decreased weight gain contrasted with insulin and sulfonylureas. Glucose is controlled better in weight gain instances. A review has shown that, on ten years of treatment, metformin-treated patients acquired around 1 kilogram, glibenclamide treated patients acquired around 3 kilograms, insulin-treated patients acquired six kg weight.[10]

Poly-Cystic Ovarian syndrome

The polycystic ovarian syndrome is often connected with insulin resistance, and starting around 1994 in PCOS treatment, metformin was put forward.[11] In 2004, the National Institute for Health and Clinical Excellence prescribed metformin for females with the polycystic ovarian syndrome and an index of body mass over 25 for infertile and anovulation cases when different treatments fail to deliver satisfactory results.[12] However, a few ensuing audits didn't show promising outcomes and didn't suggest it further or possibly as a first-line medication,[13] aside from females with glucose intolerance.[14] For the most part, the rules propose clomiphene to be the principal treatment and suggest a way of life change autonomous from drug treatment.

An orderly survey utilizing relative preliminaries like metformin clomiphene discovered equivalent outcomes for infertile cases[15]. A BMJ publication said metformin should be utilized as a subsequent option, whether the failure is seen in clomiphene treatment.[16] Besides, an enormous audit utilizing twenty-seven clinical preliminaries observed that metformin wasn't related to any increment in live birth quantity; notwithstanding, ovulation rates were enhanced, mainly if clomiphene was mixed with it and utilized.[17]

An audit suggested metformin is the best option due to constructive outcomes over insulin obstruction, hirsutism, anovulatory cases, and weight; many are regularly connected wit polycystic ovarian syndrome.[18]

Diverse preliminary plans maybe the explanations behind the problematic outcomes. For instance, considering the rate of live birth rather than pregnancy as the endpoint would have one-sided a couple of preliminaries opposing metformin.[19] Different clarification says that metformin might have diverse adequacy in various populaces.

As an Adjuvant Treatment for Cancer

Examination proposes that metformin can work as a valuable adjuvant specialist, especially in prostate and colorectal malignant growth. Several studies recognized that every growth type would probably mirror the occurrence and socioeconomics of the illness, especially the probability of showing with beginning phase sickness and analysis of diabetes mellitus. An idea of randomized clinical preliminaries utilizing metformin as an adjuvant, along with the most grounded aiding proof in prostate and colorectal malignant growth, especially those who got treatment with revolutionary radiation therapy. [20]

The variety in the adjuvant impacts of metformin as indicated by the type of cancer can be clarified by contrasts inpatient qualities and growth science. Metformin impact on AMPK

flagging has been conjectured as a significant route by which metformin applies upon the targets of malignancy impacts [21]. AMPK flagging dysregulation is also connected with the metabolic disorder [22], a group of situations that incorporate raised blood glucose before meals, hyperlipidemia, and hypertension with the obese condition [23]. Disorders related to metabolism are additionally seen building danger of fostering a few malignancies, especially colorectal disease [24], where it is likewise connected with less fortunate repeat and endurance results [25]. Moreover, it is referred to create an outcome of androgen hardship treatment in men with malignant prostate growth [26]. Metformin might further develop OS by decreasing the number of deaths due to heart ailments related to metabolic disorders; in any case, the enhancements in RFS and CSS recognized recommend an immediate target of malignant growth impact. In prostate malignancy, our review bunch examination recommends that the gainful impacts of metformin use could be restricted to those undergoing extensive radiation therapy. Pathway of AMPK is understood to assume a part in controlling cell reactions in radiation therapy, [27] considers to xenograft models of rat recommend metformin, which can further develop growth oxygenation along with like this radiations [28].

Restrictions of meta-examination incorporate innate shortcomings of practical information, significantly more incredible estimation blunders within the openness to metformin, variety in the use of metformin, and the danger of predispositionsrelatedto time [29]. Severe levels in variety among the aftereffects of research were noticed for some results researched in a large portion under types of malignancy. Affectability investigations done were to intend and investigate potential explanations behind these to illuminate further observational along with preliminary clinical plan; notwithstanding, just a few examinations were conceivable because of inadequate review digits. The overall impact of colorectal and prostate malignancy seemed to be an increment for examines along with follow-up of three years, even more noteworthy, featuring the significance of guaranteeing satisfactory span in following up for later investigations. Likenesses have been found among headache medicine investigations, in which more prominent advantages have been seen having longer follow-up [30-32]. A predetermined amount of research explored the connection about the recurrence, portion, and span of metformin in beginning phase malignancy; be that as it may, discoveries are conflicting, and further examination is needed to all the more likely comprehend this relationship.

Past examinations have recommended that an analysis of diabetes mellitus adversely affects disease results [33,34]; in this manner, consideration of non-diabetes mellitusvictims in comparator gatherings would belittle the beneficial impact that metformin produced. Attributable to lacking review sets, that was simply conceivable to examine the impact of the presence or non-appearance of the non-diabetes Mellitus patients in the comparator bunch for RFS seen in prostate disease. There was no proof of the impact.

Examination of metformin in the basic anticipation setting shows various difficulties, where the harmony between unfavorable impacts and advantages is probably going to be low good, also hard to recognize in preliminary clinical on account of less occasion rate. Whereas the high-level system can give an adequate occasion rate, where there is proof proposing that metformin needs lengthy haul use to apply target enemy of malignancy impact [35], and in this way, patients with the setup disease with more local forecasts will most likely be unable to get metformin for long which would be enough to arise helpful advantage. Accordingly, the adjuvant quality could generally be reasonable about researching counter malignant growth impacts of metformin.

Lactic Acidosis

Instances of lactic acidosis keep on being reported in patients prescribed metformin. In a study, out of a million patients prescribed metformin in the U.S., there were forty-seven reports (twenty lethal) of lactic acidosis. Out of the observed patients, forty-three were found to have renal problems (important metformin contraindication) or other risk factors for lactic acidosis other than metformin (essentially cardiovascular breakdown due to congestive causes) [36]. The death rate in patients having metformin-related lactic acidosis has all the earmarks of being ~40% and gives off an impression of being related to cardiovascular breakdown [36,37]. It was observed that out of all patients, only four didn't show other risk factors of lactic acidosis after metformin was administered. This study also indicated that out of the four case subjects, lactic acidosis had been accelerated by a scene of urosepsis. In one of these four case subjects, lactic acidosis seems to have been accelerated by a scene of urosepsis. The patients did not pass on.

A new audit of Stadesetal. [37] gives extra proof about significant metformin instances drug-related lactic-acidosis, especially lethal types identified with hidden conditions as opposed to metformin. The creators ascribed several reports about metformin related lactic-acidosis to a distribution predisposition where the broadly held tested impression that lactic acidosis caused by metformin is wrongly strengthened.
Lactic acidosis happens among non-diabetic victims in relationship with disease, malignant growth, liver disorders, kidney disappointment, and quite often a death harbinger except if the hidden situation is adjusted [38,39]. For victims who have typeII diabetes, the pace of lactic-acidosis accounted for [40], should be comparative among patients using metformin also in victims who never used metformin.

Stacpoole [41] has proposed that cases about metformin-related lactic acidosis address "responsibility by relationship" and phenformin. Stades et al. [37] ascribed several cases about metformin-related lactic acidosis to the incident that victims who have diabetes are inclined to fostering genuine ailments that lead to lactic acidosis. Besides, the absence of connection between lactate levels and metformin levels in victims[42] unequivocally proposes about metformin, which is frequently a blameless spectator. The quantity of reported instances about metformin-related lactic acidosis is little if someone thinks about ways metformin is utilized [37]. This metformin has been utilized securely in victims with serious post drug effects (43–48) can be observed as proof that its is not causing lactic acidosis. Then again, instances from the metformin gluts about lactic acidosis (32), especially among youngsters with no hazard elements[33,34], recommend metformin causing lactic acidosis whenever administered in huge portions.
Metformin infrequently, whether at any point, produces lactic acidosis at the time it is utilized according to the name. Metformin is related to lactic acidosis in victims with situations that would themselves be able to produce lactic acidosis (cardiovascular breakdown, low oxygen, Sepsis, and so on) In any case, it is difficult to decide how much, assuming any, metformin might add among the advancement of lactic acidosis. At the point where metformin is utilized according to the name, the expanded danger of lactic acidosis is zero. Else, thereabouts are near zero, so that it can't be considered in the customary clinical dynamic. Metformin would produce lactic acidosis, which is upheld by the searching of lactic acidosis in individuals whosoever has taken gluts. Accordingly, amassing the metformin in preparing kidney inadequacy may be relied upon to encourage lactic acidosis to ensure victims are in danger. If one rejects excess dosage of glutes, most instances about metformin-related lactic acidosis, especially deadly types, were likely unbrought about by the drug metformin.[49-58]

CONCLUSION

Metformin has been in need for over 60 years and is the best option drug for T2D. After the underlying idea that metformin could give CV insurance, the extra information gathered show not just that the medication can be utilized all the more generously as for renal capacity, yet that it could add to renal assurance. The information additionally demonstrates that metformin might decrease the danger of neurodegenerative conditions, and preliminaries are continuous to survey the antineoplastic properties of the medication straightforwardly. In any case, despite broad and long-standing involvement with the clinical utilization of the medication, its method of activity is as yet not completely comprehended, and the defensive activity it might apply on the CV framework, kidney, and mind and against disease is plainly generally free of its glucose-bringing down viability. For the most part, the sub-atomic systems of activity include AMPK/mTOR pathway actuation, much by what occurs under states of energy limitation. These impacts might be considered as being somewhat like those created by SGLT2is, one more class of glucose-bringing down specialists with demonstrated cardiorenal security. The metabolic impacts of metformin and SGLT2is may, to be sure, have a few similitudes. For example, utilization of SGLT2is inspires a moderate expansion in plasma grouping of ketone bodies, an elective energy substrate that has been professed to add to their CV advantage. Curiously, metformin use is additionally connected with expanded blood levels of another elective fuel substrate, lactic corrosive. On top of this, proof exists for a primary job of the cell-to-cell lactate transport, with lactate being a functioning ligand to explicit receptors through which energy is monitored, mitigating reaction, insusceptible resistance, antifibrotic activity, quality versatility, etc, can be applied. For treating type 2 diabetes mellitus, a drug of the biguanide class, Metformin, can be used. It can be used in patients who are obese and stout and in patients with ordinary kidney loads.

In patients with Diabetes mellitus (type 2), Metformin shows many benefits like weight reduction, reduced hyperinsulinemia, exaggerated fibrinolysis, improved profiles, and enhanced endothelial capacity. has a few advantages in patients with type 2 diabetes mellitus, including diminished hyperinsulinemia, weight decrease, increased fibrinolysis, further developed lipid profiles and upgraded endothelial capacity.

Even though the utilization of metformin in the condition of diabetes has raised questions on everyday wellbeing, its benefits and the new outcomes show that its nephroprotective action towards nephrotoxic specialists and its new great security date has driven scientists to acknowledge the utilization of this medication.

REFERENCES

1. Scheen AJ, Paquot N. Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes & metabolism. 2013 May 1;39(3):179-90.
2. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Annals of internal medicine. 2002 Jul 2;137(1):25-33.
3. Hundal RS, Inzucchi SE. Metformin. Drugs. 2003 Sep;63(18):1879-94.
4. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diabetes and Vascular Disease Research. 2008 Sep;5(3):157-67.
5. Rafieian-Kopaei M, Baradaran A. Combining metformin with other antioxidants may increase its renoprotective efficacy. Journal of renal injury prevention. 2013;2(2):35-6.
6. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017 Sep;60(9):1577-85.
7. Seo-Mayer PW, Thulin G, Zhang L, Alves DS, Ardito T, Kashgarian M, Caplan MJ. Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. American journal of physiology-renal physiology. 2011 Dec;301(6):F1346-57.
8. Sung JY, Choi HC. Metformin-induced AMP-activated protein kinase activation regulates phenylephrine-mediated contraction of rat aorta. Biochemical and biophysical research communications. 2012 May 11;421(3):599-604.
9. Rösen P, Wiernsperger NF. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto–Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes/metabolism research and reviews. 2006 Jul;22(4):323-30.
10. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998 Sep 12;352(9131):854-65.
11. Kidson W. Polycystic ovary syndrome: a new direction in treatment. Medical journal of Australia. 1998 Nov;169(10):537-40.
12. National Institute for Clinical Excellence. Clinical Guideline 11: Fertility: Assessment and Treatment for People with Fertility Problems. Nice; 2004.
13. Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, Stener-Victorin E, Fauser BC, Norman RJ, Teede H. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Human reproduction update. 2016 Nov 20;22(6):687-708.
14. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Human reproduction. 2008 Mar 1;23(3):462-77.
15. Palomba S, Pasquali R, Orio Jr F, Nestler JE. Clomiphene citrate, metformin or both as first- step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head- to- head randomized controlled studies and meta- analysis. Clinical endocrinology. 2009 Feb;70(2):311-21.
16. Al-Inany H, Johnson N. Drugs for anovulatory infertility in polycystic ovary syndrome.
17. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin- sensitising drugs (metformin, rosiglitazone, pioglitazone, D- chiro- inositol) for women with

polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews. 2012(5).
18. Radosh L. Drug treatments for polycystic ovary syndrome. American family physician. 2009 Apr 15;79(8):671-6.
19. Palomba S, Orio Jr F, Falbo A, Russo T, Tolino A, Zullo F. Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2007 Sep 1;92(9):3498-503.
20. Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Annals of Oncology. 2016 Dec 1;27(12):2184-95.
21. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells. Cancer research. 2007 Nov 15;67(22):10804-12.
22. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. The Journal of clinical investigation. 2013 Jul 1;123(7):2764-72.
23. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith Jr SC. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009 Oct 20;120(16):1640-5.
24. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. The American journal of clinical nutrition. 2007 Sep 1;86(3):836S-42S.
25. Shen Z, Ye Y, Bin L, Yin M, Yang X, Jiang K, Wang S. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. The American Journal of Surgery. 2010 Jul 1;200(1):59-63.
26. Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PloS one. 2015 Mar 20;10(3):e0117344.
27. Zannella VE, Cojocari D, Hilgendorf S, Vellanki RN, Chung S, Wouters BG, Koritzinsky M. AMPK regulates metabolism and survival in response to ionizing radiation. Radiotherapy and Oncology. 2011 Jun 1;99(3):293-9.
28. Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, Glicksman R, Chaib S, Zamiara P, Milosevic M, Wouters BG. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clinical cancer research. 2013 Dec 15;19(24):6741-50.
29. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes care. 2012 Dec 1;35(12):2665-73.
30. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The Lancet. 2011 Dec 17;378(9809):2081-7.
31. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Annals of internal medicine. 2013 Jul 16;159(2):77-85.

32. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet. 2010 Nov 20;376(9754):1741-50.
33. Jeon JY, Jeong DH, Park MG, Lee JW, Chu SH, Park JH, Lee MK, Sato K, Ligibel JA, Meyerhardt JA, Kim NK. Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer. PloS one. 2013 Feb 6;8(2):e55196.
34. Oh JJ, Hong SK, Lee S, Sohn SJ, Lee SE. Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy. International urology and nephrology. 2013 Feb 1;45(1):121-7.
35. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes care. 2010 Jun 1;33(6):1304-8.
36. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. New England Journal of Medicine. 1998 Jan 22;338(4):265-6.
37. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. Journal of internal medicine. 2004 Feb;255(2):179-87.
38. Stacpoole PW, Harman EM, Curry SH, Baumgartner TG, Misbin RI. Treatment of lactic acidosis with dichloroacetate. New England Journal of Medicine. 1983 Aug 18;309(7):390-6.
39. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, Duncan C, Harman EM, Henderson GN, Jenkinson S, Lachin JM. Natural history and course of acquired lactic acidosis in adults. The American journal of medicine. 1994 Jul 1;97(1):47-54.
40. . Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes care. 1998 Oct 1;21(10):1659-63.
41. . Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes care. 1998 Oct 1;21(10):1659-63.
42. . Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Drug safety. 1999 Apr;20(4):377-84.
43. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes care. 1997 Jun 1;20(6):925-8.
44. . Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. Bmj. 2005 Jun 2;330(7503):1304-5.
45. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, Rothman R. Frequency of inappropriate metformin prescriptions. Jama. 2002 May 15;287(19):2504-5.
46. Holstein A, Nahrwold D, Hinze S, Egberts EH. Contra- indications to metformin therapy are largely disregarded. Diabetic Medicine. 1999 Aug;16(8):692-6.
47. Rachmani R, Slavachevski I, Levi Z, Zadok BS, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. European Journal of Internal Medicine. 2002 Oct 1;13(7):428-33.
48. . Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and thiazolidinedione use in Medicare patients with heart failure. Jama. 2003 Jul 2;290(1):81-5.
49. Ashfaque, Aaliya Rukhsar Mohammad, Najnin Khanam, Farhan Khan, Rutuj Narendra Waghmare, and Shobha Kanhaiyalal Joshi. "Assessment of Self-Care Practices among Type 2 Diabetes Patients at a Tertiary Care Hospital - A Cross-Sectional Study." JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL

SCIENCES-JEMDS 9, no. 36 (September 7, 2020): 2630–35. https://doi.org/10.14260/jemds/2020/572.
50. Ashtankar, Poonam, V, and Punam Sawarkar. “Role of Panchatikta Panchaprasutik Niruha Vasti in Prediabetes A Case Report.” INTERNATIONAL JOURNAL OF AYURVEDIC MEDICINE 11, no. 3 (September 2020): 588–93.
51. Belsare, Anuja, Gaurav Sawarkar, and Pratiksha Mahure. “An Observational Study Protocol For The Prevalence Of Non-Insulin Dependent Diabetes Mellitus In Different Types Of Prakruti In Wardha City.” International Journal Of Modern Agriculture 9, No. 3 (2020): 96–99.
52. Inamdar, Saunitra A., Himanshi Agarwal, Sourya Acharya, and Anil Inamdar. “Coexistence of Hypertriglyceredemia and Hypercholesterolemia with Gestational Diabetes Mellitus in Pregnancy: A Case Report.” MEDICAL SCIENCE 24, no. 102 (April 2020): 594–98.
53. Jankar, Jayshri Sadashiv, Kumud Namdeorao Harley, Kanchan Manoharrao Mohod, and Vijay Yashwantrao Babar. “Association of Urinary Albumin with HbA1c Levels in Subjects of Type 2 Diabetes Mellitus in Central India.” JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 52 (December 28, 2020): 3921–25. https://doi.org/10.14260/jemds/2020/859.
54. Kamble, T. K., Ankita Kapse, Sunil Kumar, Sourya Acharya, and Aiswarya Ghule. “Study of Myocardial Performance Index in Prediabetes and Its Correlation with Other Cardiovascular Risk Factors.” JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 10 (March 9, 2020): 721–25. https://doi.org/10.14260/jemds/2020/157.
55. Thorat, Vaibhav, Imranali M. Khan, and Sakshi Gaikwad. “Platelet Rich Fibrin Matrix the Cost Effective Way to Treat Trophic Ulcer in Diabetes: A Pilot Study.” MEDICAL SCIENCE 24, no. 104 (August 2020): 2752–59.
56. Unnikrishnan, B., P. Rathi, S. K. Bhat, P. H. Nayak, N. Ravishankar, A. Singh, and O. Praveen. “Risk Factors of Gestational Diabetes Mellitus: A Hospital-Based Pair-Matched Case-Control Study in Coastal South India.” SAJOG-SOUTH AFRICAN JOURNAL OF OBSTETRICS AND GYNAECOLOGY 26, no. 1 (June 2020): 13–17. https://doi.org/10.7196/SAJOG.2020.v26i1.1518.
57. Rathi, Nikhil, Bharati Taksande, and Sunil Kumar. “Nerve Conduction Studies of Peripheral Motor and Sensory Nerves in the Subjects With Prediabetes.” JOURNAL OF ENDOCRINOLOGY AND METABOLISM 9, no. 5 (October 2019): 147–50. https://doi.org/10.14740/jem602.
58. Ray, Kausik K., Helen M. Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L. Bhatt, Vera A. Bittner, Andrzej J. Budaj, et al. “Effects of Alirocumab on Cardiovascular and Metabolic Outcomes after Acute Coronary Syndrome in Patients with or without Diabetes: A Prespecified Analysis of the ODYSSEY OUTCOMES Randomised Controlled Trial.” LANCET DIABETES & ENDOCRINOLOGY 7, no. 8 (August 2019): 618–28. https://doi.org/10.1016/S2213-8587(19)30158-5.
59. Vijaya, V., Ujjwala, K., Pallavi, D. and Choudhari, V. P. (2021) “Development of Validated RP-HPLC Method for Estimation of Empagliflozin and Metformin in Combined Formulation”, Journal of Pharmaceutical Research International, 33(60A), pp. 1-7. doi: 10.9734/jpri/2021/v33i60A34446.